•March 2, 2022•
As a new COVID-19 treatment rolls out across the country, the Illinois Department of Public Health (IDPH) continues to distribute these life-saving therapeutics equitably across the state. On February 11, 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for a new monoclonal antibody, bebtelovimab, for the treatment of COVID-19. Bebtelovimab will now join another monoclonal antibody treatment, sotrovimab, two oral antivirals, Paxlovid and molnupiravir, and a preventive drug, Evusheld, in the list of COVID-19 treatments available across Illinois.     Login or Subscribe to read the rest of this story.